Trials and Fibrillations with Dr John Mandrola

Mandrola's Top 10 Cardiology Stories of 2023 Obesity drugs, factor XI inhibitors, and procedures such as TAVR, PCI, and TEER are among the top stories of 2023, according to cardiologist John Mandrola, MD.
Experts And Viewpoints, December 20, 2023
AHA 2023 ARTESIA Doesn't Answer a Common Question in Cardiology The trial on apixaban vs aspirin in subclinical atrial fibrillation did not provide an easy answer on whether to anticoagulate patients with these common arrhythmias, writes John Mandrola, MD.
Experts And Viewpoints, November 15, 2023
AHA 2023 ORBITA-2 Saves Interventional Cardiology, Questions Guidance The second sham-controlled trial of PCI in stable CAD brings relief to the field but challenges our understanding of angina and raises the bar for trials in other specialties, says John Mandrola, MD.
Experts And Viewpoints, November 13, 2023
AHA 2023 Positive Results From SELECT Begins a New Era in Cardiology The GLP-1 agonist lowered cardiovascular events in overweight patients with CVD. While questions remain on how it works, this cardiologist sees this as a call to change societal norms around obesity.
Experts And Viewpoints, November 12, 2023
AHA 2023 Mandrola's Top Trials to Look for at AHA 2023 Semaglutide’s cardiovascular benefit in SELECT, another sham-PCI trial from the ORBITA investigators, and ARTESiA, which examines anticoagulation in subclinical atrial fibrillation, are the top AHA late-breakers for John Mandrola, MD.
Experts And Viewpoints, November 07, 2023
The Most Important Study From ESC If you treat patients, no trial at ESC is more important, according to John Mandrola, MD. The results of FRAIL-AF demonstrate the value of humility in science and the practice of evidence-based medicine.
Experts And Viewpoints, September 01, 2023
ESC 2023 AF Ablation in End-Stage HF: Too Good to Be True? Patients with AF and end-stage heart failure saw a dramatic early benefit from ablation. Some question the findings but others see a subset of patients for whom sinus rhythm makes a big difference.
Experts And Viewpoints, August 30, 2023
ESC 2023 Pulsed Field Ablation for AF Underwhelming in ADVENT Pulsed field ablation did not live up to the hype and enthusiasm of European colleagues, according to this US-based electrophysiologist, but the results of ADVENT are likely sufficient for FDA approval.
Experts And Viewpoints, August 28, 2023
ESC 2023 Supporting Evidence for a Common Practice John Mandrola, MD, reviews BUDAPEST CRT from ESC 2023, which supports the practice of upgrading patients with pacing-induced heart failure to cardiac resynchronization therapy.
Experts And Viewpoints, August 27, 2023
ESC 2023 Semaglutide in HFpEF Cleared a Low Bar Patients with heart failure with preserved ejection fraction and obesity lost weight and felt better while taking semaglutide vs placebo, but was the bar for success set too low in STEP-HFpEF?
Experts And Viewpoints, August 26, 2023
ESC 2023 How Much AF Warrants Anticoagulation? Electrophysiologist John Mandrola reviews the NOAH-AFNET 6 trial presented at the European Society of Cardiology Congress 2023, which compared edoxaban vs placebo in patients with atrial high-rate episodes.
Experts And Viewpoints, August 26, 2023
ESC 2023 Mandrola's 5 Things to Look for at ESC 2023 Electrophysiologist John Mandrola, MD, picks his top trials and themes from the upcoming European Society of Cardiology congress in Amsterdam.
Experts And Viewpoints, August 21, 2023
Are Fish Oils on the Hook for AF Risk? Some studies of fish oil supplements have shown a higher risk for atrial fibrillation with marine omega-3 fatty acids. Is it real? What are the implications for patients taking these capsules?
Experts And Viewpoints, August 10, 2023
Is the Field of Electrophysiology Stuck? The 2023 Heart Rhythm Society meeting featured hot topics such as pulsed-field ablation and late-breaking "trials" on conduction system pacing, but the data gave this electrophysiologist pause.
Experts And Viewpoints, June 01, 2023
ACC/WCC 2023 Three Surprising Studies on Exercise Can exercise be harmful? Studies from the American College of Cardiology on vigorous exercise in people with genetic heart disease and endurance exercise in middle-aged men lend more insight.
Experts And Viewpoints, March 09, 2023
ACC/WCC 2023 Transcatheter Tricuspid Repair Trial: Positive but No Benefit? Can you tell if a procedure improves quality of life without a sham control? John Mandrola, MD, sees a fatal flaw in the TRILUMINATE trial on transcatheter edge-to-edge repair of the tricuspid valve.
Experts And Viewpoints, March 05, 2023
ACC/WCC 2023 Positives and Cautions With Bempedoic Acid for Statin Intolerance Bempedoic acid was effective for reducing CV outcomes in high-risk patients intolerant to statins, but doctors should still discuss the nocebo effect or cheaper alternatives first, says John Mandrola, MD.
Experts And Viewpoints, March 04, 2023
ACC/WCC 2023 5 Things to Look for at ACC 23 Potential new lipid drugs, sports cardiology, and pulsed field ablation are among the topics that piqued Dr John Mandrola's interest at the 2023 American College of Cardiology Scientific sessions.
Experts And Viewpoints, February 27, 2023
Could a HFpEF Breakthrough Just Take a Change of Pace? In heart failure with preserved ejection fraction, a slower heart rate is presumed to help, but a new study suggests that thinking is wrong.
Experts And Viewpoints, February 10, 2023
Five Thoughts on the Damar Hamlin Collapse The cardiac arrest of Buffalo Bills defensive back Damar Hamlin has led to speculation about commotio cordis and more, but one electrophysiologist sees an opportunity for education on CPR and AEDs.
Experts And Viewpoints, January 05, 2023

No Results